Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G/Cumberland settlement

This article was originally published in The Tan Sheet

Executive Summary

Private label manufacturer Cumberland Swan Holdings will stop manufacturing, distributing and selling Procter & Gamble "look-alike" products under the terms of a consent judgment, but denies the allegations, P&G announces Aug. 31. The suit, alleging trade dress infringement and false advertising of P&G's Crest Pro-Health oral rinse brand, was filed by P&G in May and is one of several trade dress infringement suits filed by the firm this year (1"The Tan Sheet" May 8, 2006, p. 12). "We're satisfied that Cumberland Swan must now compete with its own designs and substantiate its performance claims with meaningful testing, as we do," P&G Chief Legal Officer Jim Johnson said. The remaining terms of the agreement were not disclosed...

You may also be interested in...



Gillette Drives P&G Health Care Sales Growth, Boosts Beauty Segment

The addition of Gillette Oral Care to Procter & Gamble's portfolio has driven P&G Health Care sales up 21% to $2.4 bil. for the third quarter ended March 31, the firm reported during a May 3 analyst call

Part B Drugs At Home: Medicare Policy Responds To COVID-Driven Access Concerns

Temporary policy may open door to longer term change as Medicare allows reimbursement of at-home administration of non-hospital drugs covered by Part B under a recently-released regulation aiding at encouraging telehealth during the coronavirus outbreak.

Amid Aborted Sandoz Deal, A Silver Lining For Aurobindo?

The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.

Topics

UsernamePublicRestriction

Register

PS099725

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel